# Etanercept in Hidradenitis Suppurativa

> **NCT00329823** · PHASE2 · COMPLETED · sponsor: **University of Athens** · enrollment: 10 (—)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Etanercept sc 50mg per week for 12 weeks

## Key facts

- **NCT ID:** NCT00329823
- **Lead sponsor:** University of Athens
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 10 (—)
- **Last updated:** 2006-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329823, "Etanercept in Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00329823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*